Somewhat Favorable Media Coverage Somewhat Unlikely to Affect RadNet (RDNT) Stock Price
News articles about RadNet (NASDAQ:RDNT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RadNet earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.9420325194512 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of analysts recently commented on RDNT shares. Zacks Investment Research raised RadNet from a “sell” rating to a “hold” rating in a research note on Wednesday, October 25th. TheStreet raised RadNet from a “c” rating to a “b-” rating in a research note on Thursday, August 24th. Jefferies Group raised RadNet from a “hold” rating to a “buy” rating and raised their price target for the stock from $7.00 to $12.00 in a research note on Tuesday, August 22nd. Finally, BidaskClub raised RadNet from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th.
RadNet (RDNT) opened at $10.10 on Monday. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 7.88. The stock has a market capitalization of $481.00, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 3.39 and a beta of 0.82. RadNet has a twelve month low of $5.25 and a twelve month high of $11.90.
In other news, major shareholder Sandy Nyholm Kaminsky sold 1,100,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $10.95, for a total transaction of $12,045,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John V. Crues sold 20,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $10.08, for a total value of $201,600.00. Following the transaction, the director now owns 563,781 shares of the company’s stock, valued at $5,682,912.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,269,092 shares of company stock valued at $13,814,814. 9.36% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect RadNet (RDNT) Stock Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/04/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-radnet-rdnt-stock-price-2.html.
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Stock Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related stocks with our FREE daily email newsletter.